Encore Health, LLC
Records under this name other than the patents Encore Health, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,795,706 | Methods of Treating Ocular Diseases Using Derivatives of Lipoic Acid Lapsed on the fee record Ended Aug 5, 2026 · Medium confidence | Lapsed on the fee record | Ended Aug 5, 2026 | Medium confidence |
| US 8,697,109 | Caged mercaptan and seleno-mercaptan compounds and methods of using them Lapsed on the fee record Ended Apr 15, 2026 · USPTO record | Lapsed on the fee record | Ended Apr 15, 2026 | USPTO record |
| US 7,914,815 | Method for delivery of pharmaceuticals for treating or preventing presbyopia Term ended Term ended Mar 5, 2026 · USPTO record | Term ended | Term ended Mar 5, 2026 | USPTO record |
| US 7,935,332 | Presbyopia treatment by lens alteration Formerly held Term ended Term ended Mar 22, 2025 · USPTO record | Term ended | Term ended Mar 22, 2025 | USPTO record |
| US 9,567,314 | Dithiol Compounds, Derivatives, and Uses Therefor Lapsed on the fee record Ended Feb 14, 2025 · High confidence | Lapsed on the fee record | Ended Feb 14, 2025 | High confidence |
| US 9,517,225 | Low dose lipoic acid pharmaceutical compositions and methods Lapsed on the fee record Ended Dec 13, 2024 · USPTO record | Lapsed on the fee record | Ended Dec 13, 2024 | USPTO record |
| US 9,284,305 | Methods of Treating Ocular Diseases Using Derivatives of Lipoic Acid Lapsed on the fee record Ended Mar 15, 2024 · Medium confidence | Lapsed on the fee record | Ended Mar 15, 2024 | Medium confidence |
| US 8,647,612 | Dithiol compounds, derivatives, and treatment of presbyopia Term ended Term ended Jun 3, 2023 · USPTO record | Term ended | Term ended Jun 3, 2023 | USPTO record |
| US 6,923,955 | Presbyopia treatment by lens alteration Term ended Term ended Nov 13, 2022 · USPTO record | Term ended | Term ended Nov 13, 2022 | USPTO record |
| US 8,747,829 | Presbyopia treatment by lens alteration of disulfide bonds and reduction Lapsed on the fee record Ended Jun 10, 2022 · USPTO record | Lapsed on the fee record | Ended Jun 10, 2022 | USPTO record |